Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer

被引:20
|
作者
Mezheyeuski, Artur [1 ,2 ]
Hrynchyk, Ina [3 ]
Karlberg, Mia [1 ]
Portyanko, Anna [2 ]
Egevad, Lars [1 ]
Ragnhammar, Peter [1 ]
Edler, David [4 ]
Glimelius, Bengt [5 ]
Ostman, Arne [1 ]
机构
[1] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[2] Belarusian State Med Univ, Dept Pathol, Minsk, BELARUS
[3] City Clin Pathologoanat Bur, Minsk, BELARUS
[4] Karolinska Univ Hosp Solna, Dept Mol Med & Surg, Stockholm, Sweden
[5] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
来源
SCIENTIFIC REPORTS | 2016年 / 6卷
基金
瑞典研究理事会;
关键词
THYMIDYLATE SYNTHASE EXPRESSION; COLORECTAL-CANCER; ADJUVANT THERAPY; MISMATCH REPAIR; FLUOROURACIL; CHEMOTHERAPY; INTERFACE; PATTERN; BENEFIT; MARKER;
D O I
10.1038/srep36149
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The complexity of tumor histomorphology reflects underlying tumor biology impacting on natural course and response to treatment. This study presents a method of computer-aided analysis of tissue sections, relying on multifractal (MF) analyses, of cytokeratin-stained tumor sections which quantitatively evaluates of the morphological complexity of the tumor-stroma interface. This approach was applied to colon cancer collection, from an adjuvant treatment randomized study. Metrics obtained with the method acted as independent markers for natural course of the disease, and for benefit of adjuvant treatment. Comparative analyses demonstrated that MF metrics out-performed standard histomorphological features such as tumor grade, budding and configuration of invasive front. Notably, the MF analyses-derived "alpha(max)" -metric constitutes the first response-predictive biomarker in stage II-III colon cancer showing significant interactions with treatment in analyses using a randomized trial-derived study population. Based on these results the method appears as an attractive and easy-to-implement tool for biomarker identification.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] EPSTI1 as an immune biomarker predicts the prognosis of patients with stage III colon cancer
    Wang, Xitao
    Cheng, Wei
    Zeng, Xingzhi
    Dou, Xiaolin
    Zhou, Zhongyi
    Pei, Qian
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [32] Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II-III colon cancer
    Chida, Shun
    Okayama, Hirokazu
    Noda, Masaru
    Saito, Katsuharu
    Nakajima, Takahiro
    Aoto, Keita
    Hayase, Suguru
    Momma, Tomoyuki
    Ohki, Shinji
    Kono, Koji
    Takenoshita, Seiichi
    CARCINOGENESIS, 2016, 37 (09) : 878 - 887
  • [33] A radiomics model for predicting perineural invasion in stage II-III colon cancer based on computer tomography
    Guo, Tairan
    Cheng, Bing
    Li, Yunlong
    Li, Yaqing
    Chen, Shaojie
    Lian, Guoda
    Li, Jiajia
    Gao, Ming
    Huang, Kaihong
    Huang, Yuzhou
    BMC CANCER, 2024, 24 (01)
  • [34] Raltitrexed and radiotherapy as adjuvant treatment for stage II-III rectal cancer: A feasibility study
    Lupattelli, Marco
    Maranzano, Ernesto
    Bellavita, Rita
    Natalini, Giovanni
    Corgna, Enrichetta
    Rossetti, Riccardo
    Trippa, Fabio
    Mascioni, Francesca
    Sidoni, Angelo
    Anselmo, Paola
    Buzzi, Franco
    Brugia, Mauro
    Latini, Paolo
    TUMORI JOURNAL, 2005, 91 (06): : 498 - 504
  • [35] Orthogonal MET analysis in a population-representative stage II-III colon cancer cohort: prognostic and potential therapeutic implications
    Craig, Stephanie G.
    Mende, Svenja
    Humphries, Matthew P.
    Bingham, Victoria
    Viratham Pulsawatdi, Amelie
    Loughrey, Maurice B.
    Coleman, Helen G.
    McQuaid, Stephen
    Wilson, Richard H.
    Van Schaeybroeck, Sandra
    James, Jacqueline A.
    Salto-Tellez, Manuel
    MOLECULAR ONCOLOGY, 2021, 15 (12) : 3317 - 3328
  • [36] Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer
    Catalano, V.
    Loupakis, F.
    Graziano, F.
    Bisonni, R.
    Torresi, U.
    Vincenzi, B.
    Mari, D.
    Giordani, P.
    Alessandroni, P.
    Salvatore, L.
    Fornaro, L.
    Santini, D.
    Baldelli, A. M.
    Rossi, D.
    Giustini, L.
    Silva, R. R.
    Falcone, A.
    D'Emidio, S.
    Rocchi, M.
    Fedeli, S. Luzi
    ANNALS OF ONCOLOGY, 2012, 23 (01) : 135 - U111
  • [37] PROGNOSIS OF MUCINOUS HISTOLOGY FOR PATIENTS WITH RADICALLY RESECTED STAGE II AND III COLON CANCER
    Catalano, V
    Loupakis, F.
    Bisonni, R.
    Torresi, U.
    Vincenzi, B.
    Mari, D.
    Giordani, P.
    Baldi, G.
    Santini, D.
    Giustini, L.
    Silva, R.
    Falcone, A.
    D'Emidio, S.
    Rocchi, M.
    Graziano, F.
    ANNALS OF ONCOLOGY, 2009, 20 : 61 - 61
  • [38] PROGNOSIS OF MUCINOUS HISTOLOGY FOR PATIENTS WITH RADICALLY RESECTED STAGE II AND III COLON CANCER
    Catalano, V
    Loupakis, F.
    Graziano, F.
    Bisonni, R.
    Torresi, U.
    Vincenzi, B.
    Mari, D.
    Giordani, P.
    Baldi, G.
    Santini, D.
    Giustini, L.
    Silva, R. R.
    Falcone, A.
    D'Emidio, S.
    Rocchi, M.
    Fedeli, Luzi S.
    ANNALS OF ONCOLOGY, 2009, 20
  • [39] Raltitrexed and radiotherapy as adjuvant treatment for stage II-III rectal cancer: A phase II study.
    Draghini, L.
    Lupattelli, M.
    Bellavita, R.
    Maranzano, E.
    Beneventi, S.
    D'Ambrosio, M. S.
    Trippa, F.
    Aristei, C.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S240 - S241
  • [40] P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY
    Guarneri, V.
    Piacentini, F.
    Barbieri, E.
    Frassoldati, A.
    Ficarra, G.
    D'Amico, R.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2009, 20 : 48 - 48